- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Ryan Haumschild Discusses Stakeholder Collaboration to Boost Biosimilar Adoption
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.
Transcript
How can different stakeholders work together to ensure improved biosimilar utilization across disease states?
Haumschild: I think that’s one of the things that we want to continue to expand upon. How do we get good biosimilar use in oncology, but then good biosimilar use in the immunology disease states, such as rheumatology and gastroenterology? And believe it or not, there’s different uptakes between the different disease states. If we’re using biosimilars and we’re extrapolating data to treat patients in the curative intent, how can we not extrapolate data from gastroenterology to rheumatology, and then start to look at interchangeability?
There’s going to be a never-ending appetite for data, and that’s okay because we’re data driven. How can we leverage the experiences we’ve had and the similar outcomes between reference projects and biologics, and move that into the biosimilar space, so that we can make more timely approvals? Not just wait for every single study and every single patient. And also look at switching immunogenicity and feel comfortable moving forward biosimilars across the board.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
